2126.HK
JW (Cayman) Therapeutics Co. Ltd [2126.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
2126.HK Stock Summary
Top 10 Correlated ETFs
2126.HK
Top 10 Correlated Stocks
2126.HK
In the News
2126.HK Financial details
Company Rating
Neutral
Market Cap
720.16M
Income
-1.65B
Revenue
264.24M
Book val./share
5.62
Cash/share
3.34
Dividend
-
Dividend %
-
Employees
398
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-0.99
Forward P/E
-1.55
PEG
-0.08
P/S
5.66
P/B
0.36
P/C
0.53
P/FCF
-1.29
Quick Ratio
4.63
Current Ratio
4.78
Debt / Equity
0.16
LT Debt / Equity
0.06
-
-
EPS (TTM)
-4.03
EPS next Y
-1.15
EPS next Q
-
EPS this Y
17.05%
EPS next Y
-71.57%
EPS next 5Y
-87.98%
EPS last 5Y
23.4%
Revenue last 5Y
268.3%
Revenue Q/Q
10.09%
EPS Q/Q
-7.92%
-
-
-
-
SMA20
-10.29%
SMA50
-7.58%
SMA100
-30.15%
Inst Own
-
Inst Trans
-
ROA
-30%
ROE
-33%
ROC
-0.28%
Gross Margin
40%
Oper. Margin
-478%
Profit Margin
-581%
Payout
-
Shs Outstand
402.32M
Shs Float
380.85M
-
-
-
-
Target Price
-
52W Range
1.58-3.96
52W High
-40.67%
52W Low
+78%
RSI
33.73
Rel Volume
0.48
Avg Volume
349.54K
Volume
169K
Perf Week
-5.32%
Perf Month
-11.44%
Perf Quarter
-10.1%
Perf Half Y
-7.29%
-
-
-
-
Beta
2.084
-
-
Volatility
0.03%, 0.11%
Prev Close
-0.56%
Price
1.78
Change
0.56%
2126.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.08 | 0 | 0.08 | 0.36 | |
| Net income per share | -0.72 | -9.74 | -12.61 | -1.76 | -2.06 | |
| Operating cash flow per share | -0.28 | -2.91 | -1.98 | -1.4 | -1.31 | |
| Free cash flow per share | -0.4 | -4.47 | -2.92 | -1.59 | -1.5 | |
| Cash per share | 0.36 | 3.92 | 19.95 | 4.59 | 3.39 | |
| Book value per share | -0.83 | -14.5 | 26 | 6.98 | 5.74 | |
| Tangible book value per share | -1.05 | -16.91 | 20.13 | 4.94 | 3.56 | |
| Share holders equity per share | -0.83 | -14.5 | 26 | 6.98 | 5.74 | |
| Interest debt per share | 0.16 | 22.79 | 0.84 | 0.29 | 0.61 | |
| Market cap | 7.26B | 1.28B | 2.92B | 4.37B | 1.58B | |
| Enterprise value | 7.19B | 1.1B | 412.16M | 2.68B | 471.16M | |
| P/E ratio | -26.64 | -2.02 | -1.75 | -6.22 | -1.86 | |
| Price to sales ratio | 33.78K | 232.87 | 0 | 141.96 | 10.81 | |
| POCF ratio | -68.36 | -6.76 | -11.18 | -7.79 | -2.94 | |
| PFCF ratio | -48.29 | -4.39 | -7.58 | -6.89 | -2.57 | |
| P/B Ratio | -23.19 | -1.35 | 0.85 | 1.57 | 0.67 | |
| PTB ratio | -23.19 | -1.35 | 0.85 | 1.57 | 0.67 | |
| EV to sales | 33.43K | 200.58 | 0 | 87.17 | 3.23 | |
| Enterprise value over EBITDA | -47.27 | -5.66 | -0.91 | -3.63 | -0.75 | |
| EV to operating cash flow | -67.66 | -5.82 | -1.58 | -4.78 | -0.88 | |
| EV to free cash flow | -47.79 | -3.78 | -1.07 | -4.23 | -0.77 | |
| Earnings yield | -0.04 | -0.5 | -0.57 | -0.16 | -0.54 | |
| Free cash flow yield | -0.02 | -0.23 | -0.13 | -0.15 | -0.39 | |
| Debt to equity | -0.19 | -1.57 | 0.03 | 0.04 | 0.1 | |
| Debt to assets | 0.17 | 2.22 | 0.03 | 0.04 | 0.09 | |
| Net debt to EBITDA | 0.49 | 0.91 | 5.52 | 2.28 | 1.75 | |
| Current ratio | 0.76 | 2.13 | 11.17 | 9.53 | 4.78 | |
| Interest coverage | -38.48 | 0 | 0 | -286.67 | -102.72 | |
| Income quality | 0.39 | 0.3 | 0.16 | 0.8 | 0.63 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 95.57 | 13.29 | 0 | 6.54 | 1.23 | |
| Research and developement to revenue | 353.44 | 24.82 | 0 | 13.46 | 2.8 | |
| Intangibles to total assets | 0.23 | 0.23 | 0.21 | 0.26 | 0.32 | |
| Capex to operating cash flow | 0.42 | 0.54 | 0.48 | 0.13 | 0.14 | |
| Capex to revenue | -205.34 | -18.59 | 0 | -2.37 | -0.53 | |
| Capex to depreciation | -8.64 | -5.98 | -5.36 | -1.58 | -0.94 | |
| Stock based compensation to revenue | 0 | 2.82 | 0 | 2.9 | 0.57 | |
| Graham number | 3.68 | 56.37 | 85.91 | 16.61 | 16.33 | |
| ROIC | 0.67 | -0.36 | -0.13 | -0.26 | -0.26 | |
| Return on tangible assets | -1.05 | -1.24 | -0.55 | -0.31 | -0.45 | |
| Graham Net | -1.38 | -20.86 | 17.3 | 3.82 | 2.38 | |
| Working capital | -53.98M | 138.52M | 2.41B | 1.7B | 1.17B | |
| Tangible asset value | -393.2M | -1.1B | 2.65B | 1.97B | 1.46B | |
| Net current asset value | -482.71M | -1.35B | 2.3B | 1.57B | 1.05B | |
| Invested capital | -0.19 | -1.57 | 0.03 | 0.04 | 0.1 | |
| Average receivables | 0 | 0 | 0.5 | 0.5 | 2.65M | |
| Average payables | 0 | 8.09M | 16.04M | 48.23M | 71.62M | |
| Average inventory | 0 | 0 | 477.5K | 16.18M | 35.78M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 13.29 | |
| Days payables outstanding | 0 | 0 | 0 | 1.21K | 298.71 | |
| Days of inventory on hand | 0 | 0 | 0 | 526.93 | 168.59 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 27.47 | |
| Payables turnover | 0 | 0 | 0 | 0.3 | 1.22 | |
| Inventory turnover | 0 | 0 | 0 | 0.69 | 2.17 | |
| ROE | 0.87 | 0.67 | -0.49 | -0.25 | -0.36 | |
| Capex per share | -0.12 | -1.57 | -0.94 | -0.18 | -0.19 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2021-06-30 | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.08 | 0.16 | 0.19 | 0.21 | |
| Net income per share | -0.71 | -1.06 | -1.05 | -1.01 | -0.93 | |
| Operating cash flow per share | -0.71 | -0.71 | -0.91 | -0.4 | -0.58 | |
| Free cash flow per share | -0.8 | -0.8 | -0.97 | -0.52 | -0.6 | |
| Cash per share | 6.71 | 5.66 | 4.45 | 3.78 | 3.34 | |
| Book value per share | 9.66 | 8.6 | 7.47 | 6.42 | 5.62 | |
| Tangible book value per share | 7.14 | 6.07 | 5.01 | 3.96 | 3.19 | |
| Share holders equity per share | 9.66 | 8.6 | 7.47 | 6.42 | 5.62 | |
| Interest debt per share | 0.35 | 0.36 | 0.32 | 0.67 | 0.92 | |
| Market cap | 8.21B | 4.34B | 2.82B | 1.58B | 976.41M | |
| Enterprise value | 5.71B | 2.28B | 1.22B | 342.2M | 24.62M | |
| P/E ratio | -7.31 | -2.57 | -1.64 | -0.95 | -0.64 | |
| Price to sales ratio | 0 | 140.91 | 42.77 | 19.85 | 11.13 | |
| POCF ratio | -29.22 | -15.49 | -7.62 | -9.53 | -4.1 | |
| PFCF ratio | -25.81 | -13.73 | -7.1 | -7.33 | -3.99 | |
| P/B Ratio | 2.15 | 1.27 | 0.93 | 0.6 | 0.42 | |
| PTB ratio | 2.15 | 1.27 | 0.93 | 0.6 | 0.42 | |
| EV to sales | 0 | 73.88 | 18.45 | 4.29 | 0.28 | |
| Enterprise value over EBITDA | -17.64 | -5.49 | -3.98 | -1.07 | -0.09 | |
| EV to operating cash flow | -20.32 | -8.12 | -3.28 | -2.06 | -0.1 | |
| EV to free cash flow | -17.95 | -7.2 | -3.06 | -1.58 | -0.1 | |
| Earnings yield | -0.03 | -0.1 | -0.15 | -0.26 | -0.39 | |
| Free cash flow yield | -0.04 | -0.07 | -0.14 | -0.14 | -0.25 | |
| Debt to equity | 0.04 | 0.04 | 0.04 | 0.1 | 0.16 | |
| Debt to assets | 0.03 | 0.04 | 0.04 | 0.09 | 0.13 | |
| Net debt to EBITDA | 7.72 | 4.98 | 5.25 | 3.86 | 3.56 | |
| Current ratio | 11.49 | 9.53 | 9.9 | 4.78 | 3.85 | |
| Interest coverage | 0 | 0 | 0 | 0 | 0 | |
| Income quality | 1 | 0.66 | 0.86 | 0.4 | 0.63 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 3.13 | 1.38 | 1.11 | 0.9 | |
| Research and developement to revenue | 0 | 7.43 | 2.97 | 2.66 | 2.47 | |
| Intangibles to total assets | 0.24 | 0.26 | 0.3 | 0.32 | 0.35 | |
| Capex to operating cash flow | 0.13 | 0.13 | 0.07 | 0.3 | 0.03 | |
| Capex to revenue | 0 | -1.17 | -0.41 | -0.63 | -0.08 | |
| Capex to depreciation | -2.41 | -1.16 | -0.65 | -1.17 | -0.14 | |
| Stock based compensation to revenue | 0 | 0.82 | 0.74 | 0.42 | 0.36 | |
| Graham number | 12.42 | 14.34 | 13.29 | 12.09 | 10.81 | |
| ROIC | -0.08 | -0.12 | -0.11 | -0.12 | -0.11 | |
| Return on tangible assets | -0.09 | -0.15 | -0.18 | -0.2 | -0.2 | |
| Graham Net | 5.8 | 4.76 | 3.71 | 2.74 | 2.05 | |
| Working capital | 2.49B | 2.07B | 1.72B | 1.32B | 1.07B | |
| Tangible asset value | 2.82B | 2.41B | 2.05B | 1.63B | 1.31B | |
| Net current asset value | 2.36B | 1.92B | 1.57B | 1.18B | 894.61M | |
| Invested capital | 0.04 | 0.04 | 0.04 | 0.1 | 0.16 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 66.8 | 47.52 | 41.45 | 0 | |
| Days payables outstanding | 0 | 12.98 | 13.28 | 17.43 | 15.44 | |
| Days of inventory on hand | 0 | 197.3 | 64.98 | 129.37 | 92.87 | |
| Receivables turnover | 0 | 1.35 | 1.89 | 2.17 | 87.74M | |
| Payables turnover | 0 | 6.93 | 6.78 | 5.16 | 5.83 | |
| Inventory turnover | 0 | 0.46 | 1.38 | 0.7 | 0.97 | |
| ROE | -0.07 | -0.12 | -0.14 | -0.16 | -0.16 | |
| Capex per share | -0.09 | -0.09 | -0.07 | -0.12 | -0.02 |
2126.HK Frequently Asked Questions
What is JW (Cayman) Therapeutics Co. Ltd stock symbol ?
JW (Cayman) Therapeutics Co. Ltd is a CN stock and trading under the symbol 2126.HK
What is JW (Cayman) Therapeutics Co. Ltd stock quote today ?
JW (Cayman) Therapeutics Co. Ltd stock price is $1.78 today.
Is JW (Cayman) Therapeutics Co. Ltd stock public?
Yes, JW (Cayman) Therapeutics Co. Ltd is a publicly traded company.
Company Profile
- Volume Average 349.54K
- Market Capitalization 720.16M
- Employee 398
- CEO Dr. Yiping Li M.D.
- Headquarters Shanghai,CN
- IPO Date 2020-11-03
-
Website
https://www.jwtherapeutics.com 
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
